- 10:42 PM Are stricter rules for MF advertisements on anvil?
- 10:31 PM NSE to launch new MF service system on Nov 30
- 10:16 PM India indispensable to America's future: Barack Ob...
- 10:00 PM Subir Gokarn’s agenda:Stimulus exit not to hit eco...
- 09:16 PM Worst over for India auto companies: Anand Mahindr...
- 08:52 PM Edelweiss, Tokio Marine ink insurance JV
- 08:42 PM Aviation biz to contribute 5% to rev in 3-5 years:...
- 08:24 PM Inflow of money will not help curb inflation: Bima...
- 07:17 PM MphasiS Q4 cons net profit up 33.9% at Rs 245 cr
- 06:59 PM Immediate supports for rupee at 46.20/46.10: Commt...
Aurobindo Pharma Limited is pleased to announce that it has received the tentative approval to manufacture and market Abacavir Sulfate tablets 60mg from the US Food & Drug Administration (USFDA).
The New Drug Application (NDA) 22-293 provides for the use of Abacavir Sulfate 60mg Tablets in combination with other antiretrovirals for use in pediatric patients for the treatment of HIV-1 infection.
The company had earlier received tentative approvals to Abacavir Sulfate Tablets 300mg and Abacavir Sulfate Oral Solution 20mg/mL
This is Aurobindo’s 77th ANDA approval from USFDA.
Sourced From: Aurobindo Pharma Limited
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- Mitesh Thacker's top 5 picks for trade today
- Ganeshaspeaks: Market prediction for Nov 24
- Will ITC dream run continue beyond FY10?
- Den Networks slips 22% after listing at Rs 195
- Trading in MF units to start in 15 days: SEBI
- Why LyondellBasell is a goldmine for RIL
- Experts see mkts at new highs, advise sectors
- Corrections in '10 to be more aggressive, violent: JPMorgan
- Mahindra may increase car prices due to rising input costs
Source: Business Line
- Renault to continue with M&M for Logan, says Ghosn
Source: Business Line
- Market volatility poses valuation problems: IRDA
Source: Business Line
- Punjab, Haryana buck all-India rice decline trend
Source: Business Line
